Adamas Pharma Offers Results From ADS-5102 EASE LID Trial: 'Placebo-Controlled Phase 3 Trial Demonstrated that ADS-5102 Significantly Reduced Both Dyskinesia and OFF Time at Six Months in Parkinson's Disease Patients with Levodopa-induced Dyskinesia'